MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Lixte Biotechnology Holdings Book Value 2011-2026 | LIXT
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Lixte Biotechnology Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.31 M | 5.56 M | 5.09 M | 5.01 M | 2.43 M | 4.13 M | 995 K | 215 K | 312 K | 266 K | 240 K | 1.49 M | 80 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.56 M | 80 K | 2.32 M |
Quarterly Book Value Lixte Biotechnology Holdings
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 5.56 M | 6.82 M | 8.02 M | 4.12 M | 5.09 M | 6.33 M | 7.24 M | 7.89 M | 5.23 M | 5.23 M | 5.23 M | 5.23 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 1.37 M | 1.37 M | 1.37 M | 1.37 M | 215 K | 433 K | 433 K | 433 K | 598 K | 598 K | 598 K | 598 K | 266 K | 539 K | 539 K | 539 K | 558 K | 558 K | 558 K | 558 K | 1.75 M | 1.75 M | 1.75 M | 1.75 M | 430 K | 430 K | 430 K | 430 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.02 M | 215 K | 2.55 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M |  USA |
 |
Amarin Corporation plc
AMRN
|
459 M | $ 14.67 | - | $ 6.09 B |  Irlanda |
 |
Aeterna Zentaris
AEZS
|
13.2 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | France |
 |
Cabaletta Bio
CABA
|
112 M | $ 2.82 | - | $ 283 M | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
13.5 M | $ 0.66 | -0.45 % | $ 7.56 M |  Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.86 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
CEL-SCI Corporation
CVM
|
12.9 M | $ 3.47 | - | $ 221 M | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | USA |
 |
Denali Therapeutics
DNLI
|
1.23 B | $ 19.74 | - | $ 3.25 B | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
60.9 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.29 | - | $ 329 M | Britain |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 2.85 | - | $ 592 M | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
306 M | $ 13.06 | - | $ 957 K | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
23.6 M | $ 1.09 | - | $ 22.4 M | Israel |
 |
Enochian Biosciences
ENOB
|
-21.3 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
28.6 M | $ 2.06 | - | $ 118 M | USA |
 |
Eton Pharmaceuticals
ETON
|
26.2 M | $ 23.45 | - | $ 631 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 47.55 | - | $ 4.28 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
76.6 M | $ 4.45 | - | $ 853 M | Canada |